Body distribution of 3HH-labelled dalargin bound to poly(butyl cyanoacrylate) nanoparticles after I.V. injections to mice

Schröeder, Ulrike; Schroeder, Helmut; Sabel, Bernhard A.

doi:10.1016/s0024-3205(99)00619-0

Cited by 62 publications

(27 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…33 5) Polysorbate 80 and serum protein competition, as well as the rapid nanoparticle degradation in serum/plasma, were shown to induce desorption of compounds adsorbed onto PBCA nanoparticles within a few minutes. 11,12 As an evidence of this desorption, blood pharmacokinetic profiles of drugs adsorbed onto polysorbate 80-coated PBCA nanoparticles administered intravenously were actually similar to free solutions, 25,34,35 and not at all typical of drugs associated to nonstealth colloidal drug carriers. 21,22,23,36 Therefore, as an alternative to the brain uptake of nanoparticles, we hypothesized a nanoparticle-induced nonspecific BBB permeabilization.…”

Section: General Considerationsmentioning

confidence: 98%

Drug transport to brain with targeted nanoparticles

2005

View full text Add to dashboard Cite

Summary: Nanoparticle drug carriers consist of solid biodegradable particles in size ranging from 10 to 1000 nm (50 -300 nm generally). They cannot freely diffuse through the bloodbrain barrier (BBB) and require receptor-mediated transport through brain capillary endothelium to deliver their content into the brain parenchyma. Polysorbate 80-coated polybutylcyanoacrylate nanoparticles can deliver drugs to the brain by a still debated mechanism. Despite interesting results these nanoparticles have limitations, discussed in this review, that may preclude, or at least limit, their potential clinical applications. Long-circulating nanoparticles made of methoxypoly(ethylene glycol)-polylactide or poly(lactide-co-glycolide) (mPEG-PLA/ PLGA) have a good safety profiles and provide drug-sustained release. The availability of functionalized PEG-PLA permits to prepare target-specific nanoparticles by conjugation of cell surface ligand. Using peptidomimetic antibodies to BBB transcytosis receptor, brain-targeted pegylated immunonanoparticles can now be synthesized that should make possible the delivery of entrapped actives into the brain parenchyma without inducing BBB permeability alteration. This review presents their general properties (structure, loading capacity, pharmacokinetics) and currently available methods for immunonanoparticle preparation.

show abstract

Section: General Considerationsmentioning

confidence: 98%

Drug transport to brain with targeted nanoparticles

2005

View full text Add to dashboard Cite

show abstract

“…), as a coating or linked to the Np and acting as a target or molecule for the BBB.It was reported that nanoparticles with polysorbate 80 (Tween 80, T-80) coating represented tools used for delivering drugs to brain.Schroeder et al [54] studied the Radiolabeled poly(butylcyanoacrilate) (PBCA) Np coatedwith a surfactant such as T-80 and demonstrated their ability to cross the BBB when administered intravenously. Dalargin associated with PBCA NPs and polysorbate-80 induced a potent and prolonged analgesia, which was not observed by using polystyrene NPs, but not using the PBCA NPs.…”

Section: International Journal Of Pharmaceutical and Life Sciencesmentioning

confidence: 99%

Drug Delivery to The Brain Using Polymeric Nanoparticles: A Review

Bhatt¹,

Ganesh²,

Kothiyal³

2013

Int. J. Pharma Life Sci.

View full text Add to dashboard Cite

Nanoparticle drug carriers consist of solid biodegradable particles in size ranging from 10 to 1000 nm (50-300 nm generally). The use of minute particles as drug carriers for targeted treatment has been studied over a long period of time. A selective accumulation of active substances in target tissues has been demonstrated for certain so-called nanocarrier systems that are administered bound to pharmaceutical drugs. Great expectations are placed on nanocarrier systems that can overcome natural barriers such as the blood-brain barrier (BBB) and transport the medication directly to the desired tissue and thus heal neurological diseases that were formerly incurable. Polymeric Nanoparticle have been shown to be promising carriers for CNS drug delivery due to their potential both in encapsulating drugs, hence protecting them from excretion and metabolism, and in delivering active agents across the blood -brain barrier without inflicting any damage to the barrier. Different polymers have been used and different strategies like surface modification have been done to increase the retention time of nanoparticles.

show abstract

“…It was shown in subsequent experiments with H 3 -dalargin that the absence of the polymeric coating of nanoparticles significantly reduced the delivery of the preparation to the brain. 134 The polar hydrophilic MDs tubocurarine 135 and neostigmine, 136 P-gp substrates loperamide 137 and doxorubicin, 138 and the NGF 139 protein have also delivered to the brain through the BBB using this transport system. These data support the idea that adsorption of polysorbates onto the surface of nanoparticles leads to changes in the characteristics of nanoparticle distribution, especially in relation to MD delivery to the brain.…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Nanoscale drug delivery systems and the blood–brain barrier

Alyautdin¹,

Khalin²,

Nafeeza³

et al. 2014

IJN

121

View full text Add to dashboard Cite

The protective properties of the blood–brain barrier (BBB) are conferred by the intricate architecture of its endothelium coupled with multiple specific transport systems expressed on the surface of endothelial cells (ECs) in the brain’s vasculature. When the stringent control of the BBB is disrupted, such as following EC damage, substances that are safe for peripheral tissues but toxic to neurons have easier access to the central nervous system (CNS). As a consequence, CNS disorders, including degenerative diseases, can occur independently of an individual’s age. Although the BBB is crucial in regulating the biochemical environment that is essential for maintaining neuronal integrity, it limits drug delivery to the CNS. This makes it difficult to deliver beneficial drugs across the BBB while preventing the passage of potential neurotoxins. Available options include transport of drugs across the ECs through traversing occludins and claudins in the tight junctions or by attaching drugs to one of the existing transport systems. Either way, access must specifically allow only the passage of a particular drug. In general, the BBB allows small molecules to enter the CNS; however, most drugs with the potential to treat neurological disorders other than infections have large structures. Several mechanisms, such as modifications of the built-in pumping-out system of drugs and utilization of nanocarriers and liposomes, are among the drug-delivery systems that have been tested; however, each has its limitations and constraints. This review comprehensively discusses the functional morphology of the BBB and the challenges that must be overcome by drug-delivery systems and elaborates on the potential targets, mechanisms, and formulations to improve drug delivery to the CNS.

show abstract

Body distribution of 3HH-labelled dalargin bound to poly(butyl cyanoacrylate) nanoparticles after I.V. injections to mice

Cited by 62 publications

References 16 publications

Drug transport to brain with targeted nanoparticles

Drug transport to brain with targeted nanoparticles

Drug Delivery to The Brain Using Polymeric Nanoparticles: A Review

Nanoscale drug delivery systems and the blood–brain barrier

Contact Info

Product

Resources

About

Body distribution of 3HH-labelled dalargin bound to poly(butyl cyanoacrylate) nanoparticles after I.V. injections to mice

Cited by 62 publications

References 16 publications

Drug transport to brain with targeted nanoparticles

Drug transport to brain with targeted nanoparticles

Drug Delivery to The Brain Using Polymeric Nanoparticles: A Review

Nanoscale drug delivery systems and the blood&ndash;brain barrier

Contact Info

Product

Resources

About

Nanoscale drug delivery systems and the blood–brain barrier